DOCSLIB.ORG

A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus The New England Journal of Medicine A COMPARISON OF FOUR TREATMENTS FOR GENERALIZED CONVULSIVE STATUS EPILEPTICUS DAVID M. TREIMAN, M.D., PATTI D. MEYERS, M.P.A., NANCY Y. WALTON, PH.D., JOSEPH F. COLLINS, SC.D., CINDY COLLING, R.PH., M.S., A. JAMES ROWAN, M.D., ADRIAN HANDFORTH, M.D., EDWARD FAUGHT, M.D., VINCENT P. CALABRESE, M.D., BASIM M. UTHMAN, M.D., R. EUGENE RAMSAY, M.D., AND MEENAL B. MAMDANI, M.D., FOR THE VETERANS AFFAIRS STATUS EPILEPTICUS COOPERATIVE STUDY GROUP* ABSTRACT TATUS epilepticus is a life-threatening emer- Background and Methods Although generalized gency that affects 65,0001 to 150,0002 peo- convulsive status epilepticus is a life-threatening ple in the United States each year. General- emergency, the best initial drug treatment is uncer- ized convulsive status epilepticus is the most tain. We conducted a five-year randomized, double- Scommon and most dangerous type. blind, multicenter trial of four intravenous regimens: Phenobarbital,3-5 phenytoin,6-14 diazepam plus phen- diazepam (0.15 mg per kilogram of body weight) fol- ytoin,15,16 and lorazepam17-28 have been advocated for lowed by phenytoin (18 mg per kilogram), lorazepam the initial treatment of generalized convulsive status (0.1 mg per kilogram), phenobarbital (15 mg per kil- epilepticus, and each is used by a substantial number ogram), and phenytoin (18 mg per kilogram). Pa- 3 tients were classified as having either overt general- of physicians. There are few data from controlled ized status epilepticus (defined as easily visible trials, however, to document the efficacy of these generalized convulsions) or subtle status epilepticus treatments, and they have not been directly com- (indicated by coma and ictal discharges on the elec- pared. We therefore undertook this study to com- troencephalogram, with or without subtle convulsive pare the efficacy of standard doses of these four drugs movements such as rhythmic muscle twitches or in the treatment of generalized convulsive status ep- tonic eye deviation). Treatment was considered suc- ilepticus. cessful when all motor and electroencephalographic seizure activity ceased within 20 minutes after the METHODS beginning of the drug infusion and there was no re- turn of seizure activity during the next 40 minutes. Study Design Analyses were performed with data on only the 518 In a double-blind study conducted at 16 Veterans Affairs med- patients with verified generalized convulsive status ical centers and 6 affiliated university hospitals between July 1, epilepticus as well as with data on all 570 patients 1990, and June 30, 1995, patients with generalized convulsive who were enrolled. status epilepticus were randomly assigned to receive intravenous Results Three hundred eighty-four patients had a verified diagnosis of overt generalized convulsive sta- tus epilepticus. In this group, lorazepam was suc- cessful in 64.9 percent of those assigned to receive it, From the Neurology Services of the Veterans Affairs Medical Centers in West Los Angeles, Calif. (D.M.T., P.D.M., N.Y.W., A.H.), Bronx, N.Y. phenobarbital in 58.2 percent, diazepam and pheny- (A.J.R.), Birmingham, Ala. (E.F.), Richmond, Va. (V.P.C.), Gainesville, Fla. toin in 55.8 percent, and phenytoin in 43.6 percent (B.M.U.), and Miami (R.E.R.), and the Hines Veterans Affairs Medical (P=0.02 for the overall comparison among the four Center, Chicago (M.B.M.); the Departments of Neurology of the Univer- groups). Lorazepam was significantly superior to sity of California at Los Angeles School of Medicine, Los Angeles (D.M.T., N.Y.W.), Mount Sinai College of Medicine, New York (A.J.R.), the Univer- phenytoin in a pairwise comparison (P=0.002). sity of Alabama School of Medicine, Birmingham (E.F.), the Medical Col- Among the 134 patients with a verified diagnosis of lege of Virginia, Richmond (V.P.C.), the University of Florida School of subtle generalized convulsive status epilepticus, no Medicine, Gainesville (B.M.U.), the University of Miami School of Medi- significant differences among the treatments were cine, Miami (R.E.R.), and the Loyola University School of Medicine, Chi- cago (M.B.M.); the Veterans Affairs Cooperative Studies Program Coordi- detected (range of success rates, 7.7 to 24.2 per- nating Center, Perry Point, Md. (J.F.C.); and the Veterans Affairs cent). In an intention-to-treat analysis, the differenc- Cooperative Studies Program Clinical Research Pharmacy Coordinating es among treatment groups were not significant, ei- Center, Albuquerque, N.M. (C.C.). Address reprint requests to Dr. Trei- ther among the patients with overt status epilepticus man at the Department of Neurology, University of Medicine and Dentist- ry of New Jersey–Robert Wood Johnson Medical School, 97 Paterson St., (P=0.12) or among those with subtle status epilepti- New Brunswick, NJ 08901-0019. cus (P=0.91). There were no differences among the Other authors were Pratap Yagnik, M.D. (Neurology Service, Veterans treatments with respect to recurrence during the 12- Affairs Medical Center, and Department of Neurology, Medical College of hour study period, the incidence of adverse reac- Pennsylvania — both in Philadelphia); John C. Jones, M.D. (Neurology Service, Veterans Affairs Medical Center, and Department of Neurology, tions, or the outcome at 30 days. University of Wisconsin School of Medicine — both in Madison); Eliza- Conclusions As initial intravenous treatment for beth Barry, M.D. (Neurology Service, Veterans Affairs Medical Center, and overt generalized convulsive status epilepticus, lora- Department of Neurology, University of Maryland School of Medicine — zepam is more effective than phenytoin. Although both in Baltimore); Jane G. Boggs, M.D. (Neurology Service, Veterans Af- fairs Medical Center, and Department of Neurology, Medical College of lorazepam is no more efficacious than phenobarbital Virginia — both in Richmond); and Andres M. Kanner, M.D. (Neurology or diazepam and phenytoin, it is easier to use. (N Engl Service, Veterans Affairs Medical Center, and Department of Neurology, J Med 1998;339:792-8.) University of Wisconsin School of Medicine — both in Madison). ©1998, Massachusetts Medical Society. *Other members of the study group are listed in the Appendix. 792 · September 17, 1998 The New England Journal of Medicine Downloaded from www.nejm.org at WAYNE STATE UNIVERSITY LIBRARIES on September 14, 2010. For personal use only. No other uses without permission. Copyright © 1998 Massachusetts Medical Society. All rights reserved. A COMPARISON OF FOUR TREATMENTS FOR GENERALIZED CONVULSIVE STATUS EPILEPTICUS treatment with lorazepam, phenobarbital, phenytoin, or diaz- tients was used. Electroencephalographic recording was started as epam followed by phenytoin. soon as possible after the initiation of the protocol, but treatment Overt generalized convulsive status epilepticus was defined as was never delayed until the electroencephalogram could be ob- recurrent convulsions without complete recovery between sei- tained unless it was necessary to confirm the diagnosis. Blood zures, and subtle generalized convulsive status epilepticus as the pressure, heart rate, respiratory rate, level of consciousness, and stage of generalized convulsive status when the patient is in con- seizure activity were recorded every 5 minutes for the first 20 tinuous coma but only subtle motor convulsions are seen.29 Pa- minutes after the drug infusion began and then every 10 minutes tients were classified as having one of these two types of status ep- for the next 40 minutes. Seizure activity and level of conscious- ilepticus according to the following operational definitions. Overt ness were recorded every hour thereafter until the completion of generalized convulsive status epilepticus was considered present the 12-hour study period. Blood was obtained before the initial when there were two or more generalized convulsions, without infusion, at the completion of the infusion, and 2 hours and 12 full recovery of consciousness between seizures, or continuous hours after the start of the infusion for the measurement of anti- convulsive activity for more than 10 minutes (treatment after 10 convulsant-drug concentrations. minutes of continuous seizure activity was considered essential to Treatment was considered successful if all clinical and electrical protect against neuronal and systemic damage from ongoing sei- evidence of seizure activity stopped within 20 minutes after the zure activity). Subtle generalized convulsive status epilepticus was start of the infusion and did not recur during the period from 20 considered present when the patient had coma and ictal discharges to 60 minutes after the start of treatment. Electrical seizure ac- on the electroencephalogram,30 with or without subtle convulsive tivity included any of the five ictal patterns described previously.30 movements (rhythmic twitching of the arms, legs, trunk, or facial muscles; tonic eye deviation; or nystagmoid eye jerking). If the in- Informed Consent vestigator required an electroencephalogram to diagnose general- From the institutional review board at each participating hos- ized convulsive status epilepticus, the patient was considered to pital, we obtained approval for the study and permission to waive have subtle generalized convulsive status epilepticus. the requirement for informed consent until after the initial ran- The key criterion for study entry was evidence of overt or subtle domized treatment. The rationale for the waiver was that the four generalized convulsive status epilepticus
Load more

Recommended publications
  • Status Epilepticus Clinical Pathway
    JOHNS HOPKINS ALL CHILDREN’S HOSPITAL Status Epilepticus Clinical Pathway 1 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Table of Contents 1. Rationale 2. Background 3. Diagnosis 4. Labs 5. Radiologic Studies 6. General Management 7. Status Epilepticus Pathway 8. Pharmacologic Management 9. Therapeutic Drug Monitoring 10. Inpatient Status Admission Criteria a. Admission Pathway 11. Outcome Measures 12. References Last updated: July 7, 2019 Owners: Danielle Hirsch, MD, Emergency Medicine; Jennifer Avallone, DO, Neurology This pathway is intended as a guide for physicians, physician assistants, nurse practitioners and other healthcare providers. It should be adapted to the care of specific patient based on the patient’s individualized circumstances and the practitioner’s professional judgment. 2 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Rationale This clinical pathway was developed by a consensus group of JHACH neurologists/epileptologists, emergency physicians, advanced practice providers, hospitalists, intensivists, nurses, and pharmacists to standardize the management of children treated for status epilepticus. The following clinical issues are addressed: ● When to evaluate for status epilepticus ● When to consider admission for further evaluation and treatment of status epilepticus ● When to consult Neurology, Hospitalists, or Critical Care Team for further management of status epilepticus ● When to obtain further neuroimaging for status epilepticus ● What ongoing therapy patients should receive for status epilepticus Background: Status epilepticus (SE) is the most common neurological emergency in children1 and has the potential to cause substantial morbidity and mortality. Incidence among children ranges from 17 to 23 per 100,000 annually.2 Prevalence is highest in pediatric patients from zero to four years of age.3 Ng3 acknowledges the most current definition of SE as a continuous seizure lasting more than five minutes or two or more distinct seizures without regaining awareness in between.
    [Show full text]
  • The Migraine-Epilepsy Syndrome
    medigraphic Artemisaen línea Arch Neurocien (Mex) Vol 11, No. 4: 282-287, 2006 The Migraine- Epilepsy Syndrome Arch Neurocien (Mex) Vol. 11, No. 4: 282-287, 2006 Artículo de revisión ©INNN, 2006 de caso The migraine-epilepsy syndrome Enrique Otero Siliceo†, Fernando Zermeño EL SINDROME MIGRAÑA-EPILEPSIA represent a neural exitation. Since that the glutamate has in important rol in both patologys depending of the part of the brain more affected the symptoms might RESUMEN vary from visual to abdominal phemomena. La migraña y la epilepsia tienen varios puntos en común Key words: migraine epilepsy, EEG abnormalities, sintomática clínica y genéticamente lo que ha sido glutamate, diagnosis. postulado por más de cien años. El fenómeno referido como migraña-epilepsia sugiere que exista una he first steps of a practical, approach by patofisiología común. El síndrome de migraña o physicians in recognizing and treating neuro- epilepsia tiene fenómenos comunes de dolor adominal T logic diseases are to recognithat there are jaqueca anormalidades del EE y respuesta a droga various overlaps between migraine and epilepsy. antiepilépticas. En ocasiones el paciente puede tener Epileptic seizures and classic migraine episodes may un ataque migrañoso o una convulsión o en otras occur in the same patient. Migraine and epilepsy share ambas. La comorbilidad puede explicarse por estados several genetic, clinical, evolutive and neurophysio- de hiperrexcitabilidad neural. Alteraciones electroen- logic features. A relationship between epilepsy and cefalográficas son comunes en estos estados. En migraine has been postulated for over a hundred years apariencia el glutamato tiene un papel importante tanto and the syndrome of Migraine-Epilepsy illustrates this en la migraña como en la epilepsia.
    [Show full text]
  • Migraine Triggered Seizures and Epilepsy Triggered Headache and Migraine Attacks: a Need for Re-Assessment
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central J Headache Pain (2011) 12:287–288 DOI 10.1007/s10194-011-0344-2 COMMENTARY Migraine triggered seizures and epilepsy triggered headache and migraine attacks: a need for re-assessment Paul T. G. Davies • C. P. Panayiotopoulos Received: 5 April 2011 / Accepted: 8 April 2011 / Published online: 24 April 2011 Ó The Author(s) 2011. This article is published with open access at Springerlink.com In this issue of the Journal, Belcastro and associates review Migralepsy terminology and classification issues for migralepsy, hem- icrania epileptica, post-ictal and ictal headache [1]. They According to the ICHD-II 1.5.5, ‘‘migraine-triggered sei- raise key points such as ictal headache and visual seizures zure (sometimes referred to as migralepsy)’’ denotes an are often misdiagnosed as migraine, ‘‘migralepsy’’ is unli- epileptic seizure that occurs ‘‘during or within one hour kely to exist and an ‘‘epilepsy-migraine sequence’’ is much after a migraine aura’’ [3]. However, the evidence of this more common and well documented than the dominant ‘‘migraine-seizure’’ sequence is weak and the proposed view of a ‘‘migraine-epilepsy sequence’’. Their relevant criterion of 1 h gap between the end of the ‘‘aura’’ and the proposals need appropriate attention by the committee of start of an epileptic seizure is entirely arbitrary the international classification of headache disorders Migralepsy is an old term derived from migra(ine) and (ICHD) as well as the physicians in their clinical practice (epi)lepsy, coined by Dr Douglas Davidson, but mainly because of the consequences that misdiagnosis may have on attributed to Lennox and Lennox, which we quote, ‘‘a patients.
    [Show full text]
  • Myoclonic Status Epilepticus in Juvenile Myoclonic Epilepsy
    Original article Epileptic Disord 2009; 11 (4): 309-14 Myoclonic status epilepticus in juvenile myoclonic epilepsy Julia Larch, Iris Unterberger, Gerhard Bauer, Johannes Reichsoellner, Giorgi Kuchukhidze, Eugen Trinka Department of Neurology, Medical University of Innsbruck, Austria Received April 9, 2009; Accepted November 18, 2009 ABSTRACT – Background. Myoclonic status epilepticus (MSE) is rarely found in juvenile myoclonic epilepsy (JME) and its clinical features are not well described. We aimed to analyze MSE incidence, precipitating factors and clini- cal course by studying patients with JME from a large outpatient epilepsy clinic. Methods. We retrospectively screened all patients with JME treated at the Department of Neurology, Medical University of Innsbruck, Austria between 1970 and 2007 for a history of MSE. We analyzed age, sex, age at seizure onset, seizure types, EEG, MRI/CT findings and response to antiepileptic drugs. Results. Seven patients (five women, two men; median age at time of MSE 31 years; range 17-73) with MSE out of a total of 247 patients with JME were identi- fied. The median follow-up time was seven years (range 0-35), the incidence was 3.2/1,000 patient years. Median duration of epilepsy before MSE was 26 years (range 10-58). We identified three subtypes: 1) MSE with myoclonic seizures only in two patients, 2) MSE with generalized tonic clonic seizures in three, and 3) generalized tonic clonic seizures with myoclonic absence status in two patients. All patients responded promptly to benzodiazepines. One patient had repeated episodes of MSE. Precipitating events were identified in all but one patient. Drug withdrawal was identified in four patients, one of whom had additional sleep deprivation and alcohol intake.
    [Show full text]
  • Emergency Department Management of Neuroleptic Malignant Syndrome
    The Journal of Emergency Medicine, Vol. -, No. -, pp. 1–4, 2016 Ó 2016 Elsevier Inc. All rights reserved. 0736-4679/$ - see front matter http://dx.doi.org/10.1016/j.jemermed.2015.10.042 Selected Topics: Psychiatric Emergencies PSYCHIATRIC EMERGENCIES FOR CLINICIANS: EMERGENCY DEPARTMENT MANAGEMENT OF NEUROLEPTIC MALIGNANT SYNDROME Michael P. Wilson, MD, PHD,*† Gary M. Vilke, MD,*† Stephen R. Hayden, MD,* and Kimberly Nordstrom, MD, JD‡§ *University of California at San Diego Medical Center, San Diego, California, †Department of Emergency Medicine Behavioral Emergencies Research (DEMBER) Laboratory, University of California San Diego, San Diego, California, ‡Denver Health Medical Center, Department of Behavioral Health, Psychiatric Emergency Service, Denver, Colorado, and §University of Colorado Denver, School of Medicine, Aurora, Colorado Reprint Address: Michael P. Wilson, MD, PHD, Department of Emergency Medicine, University of California at San Diego Medical Center, 200 West Arbor Drive, Mail Code #8676, San Diego, CA, 92103 , Keywords—altered mental status; neuroleptic malig- What Do You Think is Going on with This Patient? nant syndrome; dystonia; catatonia; rigidity The clinical presentation suggests neuroleptic malignant syndrome (NMS). Although first described more than 50 years ago, the diagnosis of NMS is primarily CLINICAL SCENARIO clinical (1). A 25-year-old man presents with a recent diagnosis of schizophrenia. He was discharged 1 week earlier from What Key Findings Lead to the Diagnosis? an inpatient psychiatric unit. His mother states that he has been acting ‘‘differently’’ for the past 2 days. He Clues to an NMS diagnosis include a recent diagnosis of a has not been ‘‘making any sense,’’ has felt warm to the psychotic disorder and inpatient psychiatric hospitaliza- touch, and today has been stiff and moving rigidly like tion.
    [Show full text]
  • ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions
    ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions N Specchio1, EC Wirrell2*, IE Scheffer3, R Nabbout4, K Riney5, P Samia6, SM Zuberi7, JM Wilmshurst8, E Yozawitz9, R Pressler10, E Hirsch11, S Wiebe12, JH Cross13, P Tinuper14, S Auvin15 1. Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesu’ Children’s Hospital, IRCCS, Member of European Reference Network EpiCARE, Rome, Italy 2. Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester MN, USA. 3. University of Melbourne, Austin Health and Royal Children’s Hospital, Florey Institute, Murdoch Children’s Research Institute, Melbourne, Australia. 4. Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Necker–Enfants Malades Hospital, APHP, Member of European Reference Network EpiCARE, Institut Imagine, INSERM, UMR 1163, Université de Paris, Paris, France. 5. Neurosciences Unit, Queensland Children's Hospital, South Brisbane, Queensland, Australia. Faculty of Medicine, University of Queensland, Queensland, Australia. 6. Department of Paediatrics and Child Health, Aga Khan University, East Africa. 7. Paediatric Neurosciences Research Group, Royal Hospital for Children & Institute of Health & Wellbeing, University of Glasgow, Member of European Refence Network EpiCARE, Glasgow, UK. 8. Department of Paediatric Neurology, Red Cross War Memorial Children’s Hospital, Neuroscience Institute, University of Cape Town, South Africa. 9. Isabelle Rapin Division of Child Neurology of the Saul R Korey Department of Neurology, Montefiore Medical Center, Bronx, NY USA. 10. Programme of Developmental Neurosciences, UCL NIHR BRC Great Ormond Street Institute of Child Health, Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children, London, UK 11.
    [Show full text]
  • Lafora Disease Masquerading As Hepatic Dysfunction
    Thomas Jefferson University Jefferson Digital Commons Abington Jefferson Health Papers Abington Jefferson Health 8-24-2018 Lafora Disease Masquerading as Hepatic Dysfunction Faisal Inayat Allama Iqbal Medical College Waqas Ullah Abington Jefferson Health Hanan T. Lodhi University of Nebraska at Omaha Zarak H. Khan St. Mary Mercy Hospital Livonia Ghulam Ilyas SUNY Downstate Medical Center Follow this and additional works at: https://jdc.jefferson.edu/abingtonfp See next page for additional authors Part of the Gastroenterology Commons, and the Medical Genetics Commons Let us know how access to this document benefits ouy Recommended Citation Inayat, Faisal; Ullah, Waqas; Lodhi, Hanan T.; Khan, Zarak H.; Ilyas, Ghulam; Ali, Nouman Safdar; and Abdullah, Hafez Mohammad A., "Lafora Disease Masquerading as Hepatic Dysfunction" (2018). Abington Jefferson Health Papers. Paper 7. https://jdc.jefferson.edu/abingtonfp/7 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Abington Jefferson Health Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Authors Faisal Inayat, Waqas Ullah, Hanan T. Lodhi, Zarak H. Khan, Ghulam Ilyas, Nouman Safdar Ali, and Hafez Mohammad A.
    [Show full text]
  • RLS), a Clinical Diagnosis
    Liza Ashbrook, MD February 10, 2017 Recent Advances in Neurology Patient 1 This 70-year-old man has restless leg syndrome (RLS), a clinical diagnosis. RLS affects 5-10% of the adult population of European ancestry, though likely only 2-3% come to clinical attention. The cause of RLS is not clear but it is associated with low central iron stores. This is supported by evidence from autopsy studies, CSF analysis, gradient echo MRI and transcranial ultrasound. A family history of RLS is reported in 63-92% of individuals suggesting a strong genetic component as well. RLS is typically separated into intermittent symptoms, defined by fewer than twice/week over a year and chronic symptoms. When symptoms are only bothersome intermittently, such as a long plane flight, medications such as carbidopa/levodopa 25/100 can be very effective, however use more than twice weekly can lead to augmentation. Benzodiazepines and hypnotics are also recommended only for as needed use. Periodic limb movements (PLMs) occur in up to 80% of patients with RLS and are diagnosed by polysomnography. These are stereotyped kicking movements and patients are usually unaware of their presence though bed partners may complain. A small subset of those with PLMs are thought to have periodic leg movement disorder (PLMD), defined by PLMs causing either night time or daytime impairment. Other causes of insomnia and hypersomnia must be ruled out and those with RLS cannot have a diagnosis of PLMD. PLMs are of unclear clinical significance and may be a part of normal aging or an epiphenomenon. RLS and PLMs are commonly confused.
    [Show full text]
  • Neuroleptic Malignant Syndrome in a Patient
    Psychiatria Danubina, 2018; Vol. 30, Suppl. 7, pp 415-417 Conference paper © Medicinska naklada - Zagreb, Croatia NEUROLEPTIC MALIGNANT SYNDROME IN A PATIENT TREATED WITH CLOTIAPINE Clémentine Lantin, Miriam Franco, François-Xavier Dekeuleneer, Didier Chamart & Juan Martin Tecco Mental Health Unit, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage (CHUP-MB), Mons, Belgium SUMMARY Background: Neuroleptic malignant syndrome (NMS), which is linked to the use of antipsychotic medication, is a potentially lethal neurological emergency. The interest of our study is that NMS induced by the use of clotiapine has never previously been described. Subjects and methods: We present the case of a 61-year old man whose sleep disorders were treated with clotiapine 40 mg/day. After 7 days of taking 40 mg clotiapine, the patient presented with a deterioration of his general health which had gradually taken hold, with altered consciousness accompanied by generalised muscle rigidity and hypersalivation. Laboratory blood tests revealed elevated levels of Creatine Phosphokinase (CPK) at 812 U/l. The patient was diagnosed with NMS and treated accordingly. Results: The mechanism that underlies the appearance of NMS remains largely unknown. Clotiapine is a second-generation antipsychotic, first released onto the market in the 1970s, and is available in a few countries, including Belgium. NMS is treated as a medical emergency due to the possibility of morbidity and death. The first step in the treatment of NMS consists in withholding the agent suspected of provoking the symptoms. Conclusions: NMS is difficult to diagnose due to a great variability in clinical presentations and the absence of specific tests and laboratory results.
    [Show full text]
  • Download Download
    Ziprasidone Associated Neuroleptic KANSAS JOURNAL of MEDICINE Malignant Syndrome Jeffrey D. Bell, M.D.1, Chancen Hall, D.O.2, Justin Sandall, D.O.2 1Beaver Medical Group, Redland, CA NMS, serotonin syndrome (SS), non-convulsive status epilepticus, 2University of Kansas School of Medicine-Wichita, Wichita, KS or other central nervous system (CNS) pathology. Blood, urine, and Department of Anesthesiology sputum cultures were obtained, and she was considered for a lumbar Received Oct. 7, 2019; Accepted for publication Dec. 21, 2020; Published online March 19, 2021 puncture to evaluate for meningitis. In addition, medical records were https://doi.org/10.17161/kjm.vol1411970 obtained from the outside facility and showed she had been receiving INTRODUCTION increasing doses of ziprasidone along with haloperidol, lithium, dulox- Neuroleptic malignant syndrome (NMS) is a severe and potentially etine, oxybutynin, and baclofen. lethal disorder due to an adverse reaction to dopamine receptor antag- Once this information was received and in consultation with our 1 onism or the rapid withdrawal of dopaminergic medications. While neurology and psychiatry colleagues, the patient was treated for a pre- 1 2 incidence is estimated to be 0.02% generally and 0.2% among neu- sumptive diagnosis of NMS with IV bromocriptine 10 mg every six roleptic users, NMS continues to be an unpredictable and potentially hours and a one-time dose of IV dantrolene 2.5 mg/kg, discontinuation life-threatening condition of which case reports continue to be a main of possible causative agents, a cooling blanket and antipyretics, and IV 3 source of information for clinicians. fluids. Despite the advent of second-generation antipsychotics (SGA), SS, which presents with dysautonomia and hyperreflexia in the NMS continues to be a rare yet severe adverse reaction to neurolep- setting of serotonergic medications, was considered for this patient, 4 tics.
    [Show full text]
  • Unusual Course of Lafora Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Groningen University of Groningen Unusual course of Lafora disease Zutt, Rodi; Drost, Gea; Vos, Yvonne; Elting, J.W.J.; Miedema, I.; tijssen, m.a.; Brouwer, Oebele; de Jong, Bauke M Published in: epilepsia open DOI: 10.1002/epi4.12009 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Zutt, R., Drost, G., Vos, Y., Elting, J. W. J., Miedema, I., tijssen, M. A., ... de Jong, B. M. (2016). Unusual course of Lafora disease. epilepsia open, 1(3-4), 136-139. https://doi.org/10.1002/epi4.12009 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
    [Show full text]
  • Clinical Decision Making in Seizures and Status Epilepticus
    January 2015 Clinical Decision Making Volume 17, Number 1 Authors In Seizures And Felipe Teran, MD Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Faculty, Emergency Department, Clínica Status Epilepticus Alemana, Santiago, Chile Katrina Harper-Kirksey, MD Abstract Anesthesia Critical Care Fellow, Department of Anesthesia, Stanford Hospital and Clinics, Stanford, CA Andy Jagoda, MD, FACEP Seizures and status epilepticus are frequent neurologic emergen- Professor and Chair, Department of Emergency Medicine, Icahn cies in the emergency department, accounting for 1% of all emer- School of Medicine at Mount Sinai, New York, NY; Medical Director, Mount Sinai Hospital, New York, NY gency department visits. The management of this time-sensitive and potentially life-threatening condition is challenging for both Peer Reviewers prehospital providers and emergency clinicians. The approach to J. Stephen Huff, MD Professor of Emergency Medicine and Neurology, University of seizing patients begins with differentiating seizure activity from Virginia, Charlottesville, VA mimics and follows with identifying potential secondary etiolo- Jason McMullan, MD gies, such as alcohol-related seizures. The approach to the patient Assistant Professor, Department of Emergency Medicine, University of in status epilepticus and the patient with nonconvulsive status Cincinnati, Cincinnati, OH epilepticus constitutes a special clinical challenge. This review CME Objectives summarizes the best available evidence and recommendations Upon completion of this article, you should be able to: regarding diagnosis and resuscitation of the seizing patient in the 1. Describe the diagnostic approach to patients who have recovered from a seizure and patients in status epilepticus. emergency setting. 2. Recognize and treat patients with alcohol withdrawal seizures.
    [Show full text]